Intra-Cellular Therapies, Inc., based in the United States, is a high-risk pharmaceutical company known for developing innovative drugs to treat central nervous system diseases. With a strong focus on ESG, the company uses proprietary chemistry platforms to deliver small-molecule drugs for neuropsychiatric and neurological disorders. Specializing in neurodegenerative diseases, Intra-Cellular is dedicated to discovering and developing treatments for a range of neurological and psychiatric conditions.